证券代码：688065 证券简称：凯赛生物 公告编号：2025-046 上海凯赛生物技术股份有限公司 关于完成董事会换届选举、聘任高级管理人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券交 易所科创板股票上市规则》（以下简称"《上市规则》"）、《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》等法律、法规、规范性文件及《上 海凯赛生物技术股份有限公司章程》（以下简称"《公司章程》"）等有关规定，上 海凯赛生物技术股份有限公司（下称"公司"）于 2025 年 8 月 18 日召开 2025 年第二次临时股东大会，选举产生第三届董事会成员。次日，公司召开第三届董 事会第一次会议，选举产生董事长、副董事长、各专门委员会委员及召集人，并 聘任高级管理人员。现将相关情况公告如下： 国证券监督管理委员会、证券交易所处罚的情形。其中董事会秘书臧慧卿女士已 取得上海证券交易所颁发的《科创板董事会秘书资格证书》，且其任职资格已经 通过上海证券交易 ...

Core Viewpoint - Kasei Biotech (688065.SH), recognized as the "first synthetic biology stock" on the STAR Market, has shown continuous growth in its operating performance, with significant increases in both revenue and net profit in the first half of 2025 [1][2] Financial Performance - In the first half of 2025, Kasei Biotech achieved total revenue of 1.671 billion yuan, representing a year-on-year growth of 15.68%, and a net profit of 309 million yuan, up 24.74% year-on-year [1][2] - The company's revenue has grown from 1.497 billion yuan in 2020 to 2.958 billion yuan in 2024, marking a 97.6% increase over the period [2] - In 2024, the core product, long-chain dicarboxylic acid series, generated revenue of 2.670 billion yuan, with a growth rate of 39.94% [3] Research and Development - Kasei Biotech has invested a total of 951 million yuan in R&D from 2020 to the first half of 2025, with a consistent increase in annual investment [4] - The company has obtained a total of 516 patents by the end of the first half of 2025, with 77.5% being invention patents, which strengthens its technological barriers [5][6] Asset Growth and Capital Operations - As of the end of the first half of 2025, Kasei Biotech's total assets reached 23.82 billion yuan, a 30.02% increase compared to the same period last year [1][6] - The company successfully raised 5.915 billion yuan through a private placement to fund the second phase of its 900,000-ton bio-based polyamide project and upgrade its R&D center [6]

Meeting Overview - The shareholders' meeting of Shanghai Kaisa Biotechnology Co., Ltd. was held on August 18, 2025, in Shanghai [1] - A total of 171 ordinary shareholders attended the meeting, holding 517,786,578 voting rights, which represents 72.02% of the company's total voting rights [1] Voting Results - All non-cumulative voting proposals were approved with significant support, including: - 99.5553% of ordinary shareholders voted in favor of the first proposal, with 2,255,339 votes against and 47,043 abstentions [1] - The second proposal received 99.5533% approval, with 2,265,639 votes against and 47,043 abstentions [1] - The third proposal had 99.5576% approval, with 2,243,639 votes against and 47,043 abstentions [1] Election of Directors - The meeting included the election of several directors, all of which were approved: - XIUCAI LIU was elected as a non-independent director [2] - DENG WEIDONG, LU YIYANG, ZANG HUIQING, and YANG CHEN were also elected as non-independent directors [3] - WU XIANGYANG, SHANG JIANGANG, and LIAN LISHUAI were elected as independent directors [3] Legal Compliance - The meeting was conducted in accordance with relevant laws, regulations, and the company's articles of association, ensuring the legality and validity of the proceedings and voting results [3]

Core Viewpoint - The legal opinion letter from Shanghai Jintiancheng Law Firm confirms the legality of the procedures and qualifications for the 2025 Second Extraordinary General Meeting of Shanghai Kaisa Biotechnology Co., Ltd. [1][6] Group 1: Meeting Procedures - The meeting was proposed and convened by the board of directors, with the notice published on August 2, 2025 [3][4]. - The meeting combined on-site and online voting, held on August 18, 2025, at a specified location [4][6]. - The legal opinion confirms that the convening and holding procedures comply with relevant laws and regulations [6]. Group 2: Attendance and Qualifications - A total of 171 shareholders and representatives attended the meeting, representing 517,786,578 shares, which is 72.02% of the total voting shares [5]. - The legal opinion verifies that all attendees had valid qualifications according to applicable laws and the company's articles of association [5][6]. Group 3: Proposals and Voting Results - The meeting included proposals for amendments to various internal rules and the election of new board members [7][8]. - Voting results showed that all proposals were approved, with significant support from shareholders [12]. - Specific voting results indicated that the proposals received over 515 million votes in favor, demonstrating strong shareholder backing [8][12].

法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 上海市锦天城律师事务所 关于上海凯赛生物技术股份有限公司 2025 年第二次临时股东大会的 关于上海凯赛生物技术股份有限公司 1 上海市锦天城律师事务所 法律意见书 2025 年第二次临时股东大会的 法律意见书 致：上海凯赛生物技术股份有限公司 根据《中华人民共和国证券法（2019 年修订）》（以下简称"《证券法》"） 《中华人民共和国公司法（2023 年修订）》（以下简称"《公司法》"）和中 国证券监督管理委员会《上市公司股东会规则》等法律、法规和其他有关规范性 文件的要求，上海市锦天城律师事务所（以下简称"本所"）接受上海凯赛生物 技术股份有限公司（以下简称"凯赛生物"或"公司"）的委托，指派律师参加 公司 2025 年第二次临时股东大会（以下简称"本次股东大会"或"本次会议"）。 为出具本《法律意见书》，本所声明如下： 1、本所律师仅对本次股东大会的召集程序、召开程序、出席会议 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-045 上海凯赛生物技术股份有限公司 2025年第二次临时股东大会决议公告 | 1、出席会议的股东和代理人人数 | 171 | | --- | --- | | 普通股股东人数 | 171 | | 2、出席会议的股东所持有的表决权数量 | 517,786,578 | | 普通股股东所持有表决权数量 | 517,786,578 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 72.02 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 72.02 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事长 XIUCAI LIU(刘修才)博士主持。本次股东大会 的召开及表决方式符合《中华人民共和国公司法》等法律法规及《公司章程》的 有关规定。 （五） 公司董事、监事和董事会秘书的出席情况 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否 ...

Group 1 - Kanto Denka Kogyo Co., Ltd. announced an explosion and severe fire at its nitrogen trifluoride (NF3) production facility in Shibukawa, Gunma Prefecture, Japan, on August 7, resulting in partial damage to one production line and a continued halt in operations as per authorities' instructions [2] - Historical data indicates that the chemical sector tends to outperform the CSI 300 index around the Producer Price Index (PPI) turning points, suggesting that asset allocation plays a significant role in this performance [2] - The current situation is at a PPI monthly year-on-year turning point, but a return to positive year-on-year growth may take over six months, prompting a need to identify new main investment themes while increasing allocation to the chemical sector [2] Group 2 - As of July 31, 2025, the top ten weighted stocks in the CSI Sub-Industry Chemical Theme Index (000813) include Wanhua Chemical, Yilong Co., Ltd., Juhua Co., Ltd., and others, collectively accounting for 43.54% of the index [3] - The Chemical ETF (159870) closely tracks the CSI Sub-Industry Chemical Theme Index, which consists of seven sub-indices reflecting the overall performance of major listed companies in related sub-industries [3]

Group 1 - The chemical sector experienced a volatile upward trend on August 18, with the Chemical ETF (516020) opening high and fluctuating in positive territory, rising over 1% at one point and closing up 0.59% [1] - Key stocks in the sector included lithium battery and fluorochemical companies, with notable gains from Xinzhou Bang and Kaisa Bio, both up over 6%, and other companies like Juhua Co. and Lianhong Xinke rising over 4% [1][2] - The chemical ETF's underlying index had a price-to-book ratio of 2.11, indicating a low valuation at the 29.22 percentile over the past decade, suggesting attractive long-term investment opportunities [3] Group 2 - Analysts predict that the chemical industry will see a stabilization in domestic demand due to the implementation of various expansion policies, although competition on the supply side may lead to weaker product prices and lower capacity utilization [1][3] - The chemical market is expected to undergo a phase of recovery, particularly in sub-sectors like pesticides, organic silicon, and polyester filament, as the industry addresses issues of overcapacity and excessive competition [3] - The Chemical ETF (516020) provides a diversified investment approach, covering various sub-sectors and concentrating nearly 50% of its holdings in large-cap leading stocks, which allows investors to capitalize on strong market trends [4]

Key Points Summary of Kasei Bio's Conference Call Company Overview - **Company**: Kasei Bio - **Industry**: Biochemical Manufacturing Financial Performance - **Revenue**: 1.671 billion CNY in H1 2025, up 15.68% YoY [2][37] - **Gross Profit**: 565 million CNY, up 25.4% YoY [2][37] - **Net Profit**: 309 million CNY, up 24.74% YoY [2][37] - **Total Assets**: 23.821 billion CNY, up 25.23% from the beginning of the year [2][37] - **Net Assets**: 17.453 billion CNY, up 51.67% from the beginning of the year [37] - **Fundraising**: Completed a private placement raising 5.915 billion CNY [2][37] Business Segments and Developments Long Carbon Chain Dicarboxylic Acids - **Market Demand**: Strong demand for long carbon chain dicarboxylic acids, with plans for timely capacity expansion [2][6] - **Capacities**: The 40,000-ton caproic acid project is nearing full production, with positive sales performance [3][5] Biobased Polyamide - **Collaborations**: Established a task force with China Merchants Group to advance pilot projects in textiles, construction, and renewable energy [2][4] - **Market Adoption**: Brands like Hailan Home have begun using biobased polyamide materials [2][21] Composite Materials - **Product Development**: Progress in composite materials focusing on modern construction, logistics, and renewable energy [2][5] - **Commercialization**: Long carbon chain nylon has entered mass production for commercial vehicle applications [2][9] Battery Shell Project - **Partnership with CATL**: The project in Hefei is progressing with 18 planned production lines, with the first phase consisting of 4 lines [2][7][8] - **Production Capacity**: Expected to produce 410,000 tons of biobased composite materials annually [7] Solar and Energy Storage Solutions - **Supply Chain**: Established supply chains for photovoltaic frames and developed complete solutions for energy storage [11][12] Market and Regulatory Environment - **Export Stability**: Tariff issues have had minimal impact on export business, maintaining stable export ratios [20][21] - **Intellectual Property**: Victory in a European IP lawsuit positively impacts business in the European market [21] Future Outlook - **Expansion Plans**: Plans to expand production capacity for long carbon chain dicarboxylic acids and biobased polyamide [6][38] - **Policy Support**: Anticipated government policies to support biomanufacturing, including tax incentives [19] - **Market Positioning**: Aiming to become a leading supplier in the domestic market with over 50% market share in dicarboxylic acids by year-end [16] Challenges and Strategies - **Market Acceptance**: Challenges in promoting new materials due to customer adaptation to new technologies [34][35] - **Cost Efficiency**: Focus on reducing costs and improving efficiency through technological innovations [17][18] Conclusion Kasei Bio is positioned for growth with strong financial performance, ongoing collaborations, and a focus on innovative biobased materials. The company is navigating market challenges while leveraging regulatory support to enhance its competitive edge in the biochemical manufacturing industry.

Group 1: Market Dynamics - The People's Bank of China (PBOC) supports more private technology enterprises and private equity investment institutions to issue bonds for financing, aiming to enhance the bond market and facilitate financing for quality private enterprises [2] - The PBOC emphasizes the development of a multi-tiered bond market and the promotion of the Panda bond market, while also advancing the internationalization of the Renminbi [2] Group 2: Company Developments - OpenAI plans to invest trillions of dollars in infrastructure for developing and operating AI services, indicating a significant commitment to data center construction [3] - Huahong Semiconductor is planning to acquire the controlling stake in Shanghai Huali Microelectronics to resolve competition issues, with its stock suspended for up to 10 trading days [9] - Shengyi Technology reported a 91% increase in revenue to 3.769 billion yuan and a 452% increase in net profit to 531 million yuan for the first half of 2025 [9] - Chipone Technology achieved a 40.32% revenue growth to 636 million yuan and a 106.02% increase in net profit to 90.49 million yuan in the same period [9] - Tianyue Advanced confirmed its H-share issuance price at 42.80 HKD per share, with trading expected to start on August 20, 2025 [11] Group 3: Technological Innovations - The first humanoid robot, "Embodied Tiangong Ultra," won the 100-meter sprint at the World Humanoid Robot Games with a time of 21.50 seconds, showcasing advancements in autonomous navigation [4] - The Chinese space station successfully utilized the "Wukong AI" model during an extravehicular activity, providing intelligent support to astronauts [5] - Shanghai Lingang launched its first batch of autonomous smart connected taxis, covering 58 locations with a fare structure starting at 16 yuan for trips under 5 kilometers [6] - ZhiYuan Robotics launched the OmniHand 2025 series, aimed at enhancing industrial manufacturing and service interactions, with a promotional price drop [7] Group 4: Industry Trends - Several photovoltaic companies have been invited to participate in a discussion organized by relevant authorities, indicating ongoing developments in the solar energy sector [8] - Tsinghua University achieved a significant breakthrough in quantum computing, developing a programming architecture for arbitrary two-qubit gates [15][16] - A collaborative effort led by Karolinska Institute has resulted in a method for designing new antibiotics using generative AI, addressing antibiotic resistance [16]